- 6-12 months induction and maintenance
- 3-6 months for remission induction
- 74%
China versus the U.S.
- China clinical rate
- $1,500 – $5,000
- $3,250
- United States
- $5,000 – $20,000
- $12,500
- You save
- ~74%
- $9,250 per procedure
Prices are approximate ranges. Actual cost depends on hospital, surgeon, materials, and case complexity.
What the procedure involves.
Specialized vasculitis treatment covering ANCA-associated vasculitis, Takayasu arteritis, and Behcet's disease using rituximab, cyclophosphamide, and novel targeted agents. Chinese hospitals have particular expertise in Takayasu arteritis and Behcet's disease, which are more prevalent in East Asian populations. Advanced vascular imaging and biopsy capabilities ensure accurate diagnosis and monitoring.
Step by step.
Vasculitis Classification
ANCA testing, tissue biopsy, CTA/MRA vascular imaging, and organ damage assessment
Remission Induction
High-dose corticosteroids with cyclophosphamide or rituximab depending on vasculitis type and severity
Maintenance Therapy
Transition to azathioprine, mycophenolate, or rituximab maintenance with steroid tapering
Vascular Monitoring
Regular imaging surveillance, inflammatory marker tracking, and organ function monitoring
- Expertise in Asian-prevalent vasculitis types (Takayasu, Behcet's)
- Advanced vascular imaging at lower cost
- Access to rituximab and novel complement inhibitors
- Comprehensive multiorgan monitoring protocols
- Severe infection risk during induction therapy
- Organ damage from undertreated disease
- Cyclophosphamide risks including bladder toxicity and infertility
- Relapse risk after treatment discontinuation
Ask the AI for hospitals that handle vasculitis treatment.
Prices shown are approximate ranges for reference only. Actual costs vary by hospital, complexity, and individual patient needs. Always consult with healthcare professionals for medical decisions.